Survival of Older Adults With Newly Diagnosed Acute Myeloid Leukemia: Effect of Using Multiagent Versus Single-agent Chemotherapy.

[1]  V. Bhatt,et al.  Treatment Strategies for Therapy-related Acute Myeloid Leukemia. , 2019, Clinical lymphoma, myeloma & leukemia.

[2]  H. Kantarjian,et al.  Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia , 2019, Cancer.

[3]  V. Bhatt.  Integrating Geriatric Assessment and Genetic Profiling to Personalize Therapy Selection in Older Adults with Acute Myeloid Leukemia (AML) , 2019, Blood.

[4]  V. Bhatt.  Cancer in older adults: understanding cause and effects of chemotherapy-related toxicities. , 2019, Future oncology.

[5]  V. Bhatt,et al.  Intensity of chemotherapy for the initial management of newly diagnosed acute myeloid leukemia in older patients. , 2019, Future oncology.

[6]  E. Estey,et al.  More Versus Less Therapy for Older Adults With Acute Myeloid Leukemia: New Perspectives on an Old Debate. , 2019, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[7]  V. Bhatt.  Personalizing therapy for older adults with acute myeloid leukemia: Role of geriatric assessment and genetic profiling. , 2019, Cancer treatment reviews.

[8]  J. Armitage,et al.  Treatment patterns and outcomes of octogenarian patients with acute myeloid leukemia , 2019, American journal of hematology.

[9]  M. Jongen‐Lavrencic,et al.  Intensive treatment and trial participation in elderly acute myeloid leukemia patients: A population-based analysis in The Netherlands. , 2018, Cancer epidemiology.

[10]  F. Appelbaum,et al.  Early mortality and overall survival of acute myeloid leukemia based on facility type , 2017, American journal of hematology.

[11]  E. Estey,et al.  Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic Models , 2016 .

[12]  H. Kantarjian,et al.  Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia. , 2016, Clinical Lymphoma, Myeloma & Leukemia.

[13]  D. Bourn,et al.  Incidence and outcomes for adults diagnosed with acute myeloid leukemia in the north of England: a real world study , 2016, Leukemia & lymphoma.

[14]  R. Greil,et al.  International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. , 2015, Blood.

[15]  C. Reyes,et al.  Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States , 2015, Annals of Hematology.

[16]  J. Williamson,et al.  Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. , 2010, Blood.

[17]  H. Kantarjian,et al.  Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. , 2012, Blood.

[18]  D. Weisdorf,et al.  Survival for older patients with acute myeloid leukemia: a population-based study , 2012, Haematologica.

[19]  H. Döhner,et al.  High-dose daunorubicin in older patients with acute myeloid leukemia. , 2009, The New England journal of medicine.

[20]  M. Minden,et al.  Outcomes and quality of care in acute myeloid leukemia over 40 years , 2009, Cancer.

[21]  Sören Lehmann,et al.  Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. , 2009, Blood.